Important points to consider when choosing your first, second, third and beyond line of therapy(ies) for advanced oncogene driven lung cancers. The indications and evidence for sequencing in local ablative therapies will be covered. NSCLC experience will be drawn upon including efficacy, tolerability, and mechanisms of resistance to ALK inhibitors and interpatient biology. Such an evolution in therapeutics is informing our expansion across oncogene driven lung cancers and beyond.